上海医药(02607.HK)子公司成为氨磺必利口崩片上市许可持有人

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd. (referred to as "Shiyou"), has received the approval notice from the National Medical Products Administration for the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou [1] Group 1 - The approval notice includes notification numbers: 2025B04804 and 2025B04815 [1]